Find Eluxadoline manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

0

FDF

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

PATENTS & EXCLUSIVITIES

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

Finished Drug Prices

NA

116 RELATED EXCIPIENT COMPANIES

201EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 864821-90-9, Viberzi, Truberzi, Jnj-27018966, Eluxadoline [usan], Jnj 27018966
Molecular Formula
C32H35N5O5
Molecular Weight
569.6  g/mol
InChI Key
QFNHIDANIVGXPE-FNZWTVRRSA-N
FDA UNII
45TPJ4MBQ1

Eluxadoline
Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system and peripherally in the gastrointestinal system. Agonism of peripheral mu-opioid receptors results in reduced colonic motility, while antagonism of central delta-opioid receptors results in improved analgesia, making eluxadoline usable for the symptoms of both pain and diarrhea characteristic of IBS-D. Marketed under the tradename Viberzi (FDA), eluxadoline is an antimotility agent that decreases bowel contractions, inhibits colonic transit, and reduces uid/ion secretion resulting in improved symptoms of abdominal pain and reductions in the Bristol Stool Scale.
Eluxadoline is a mu-Opioid Receptor Agonist. The mechanism of action of eluxadoline is as an Opioid mu-Receptor Agonist.
1 2D Structure

Eluxadoline

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
5-[[[(2S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)propanoyl]-[(1S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid
2.1.2 InChI
InChI=1S/C32H35N5O5/c1-18-12-23(29(34)38)13-19(2)24(18)15-26(33)31(39)37(17-21-10-11-28(42-4)25(14-21)32(40)41)20(3)30-35-16-27(36-30)22-8-6-5-7-9-22/h5-14,16,20,26H,15,17,33H2,1-4H3,(H2,34,38)(H,35,36)(H,40,41)/t20-,26-/m0/s1
2.1.3 InChI Key
QFNHIDANIVGXPE-FNZWTVRRSA-N
2.1.4 Canonical SMILES
CC1=CC(=CC(=C1CC(C(=O)N(CC2=CC(=C(C=C2)OC)C(=O)O)C(C)C3=NC=C(N3)C4=CC=CC=C4)N)C)C(=O)N
2.1.5 Isomeric SMILES
CC1=CC(=CC(=C1C[C@@H](C(=O)N(CC2=CC(=C(C=C2)OC)C(=O)O)[C@@H](C)C3=NC=C(N3)C4=CC=CC=C4)N)C)C(=O)N
2.2 Other Identifiers
2.2.1 UNII
45TPJ4MBQ1
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Viberzi

2.3.2 Depositor-Supplied Synonyms

1. 864821-90-9

2. Viberzi

3. Truberzi

4. Jnj-27018966

5. Eluxadoline [usan]

6. Jnj 27018966

7. 45tpj4mbq1

8. Chembl2159122

9. Chebi:85980

10. 864821-90-9 (free Base)

11. Eluxadoline (usan)

12. 5-(((s)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)-n-((s)-1-(5-phenyl-1h-imidazol-2-yl)ethyl)propanamido)methyl)-2-methoxybenzoic Acid

13. 5-({(4-carbamoyl-2,6-dimethyl-l-phenylalanyl)[(1s)-1-(4-phenyl-1h-imidazol-2-yl)ethyl]amino}methyl)-2-methoxybenzoic Acid

14. Benzoic Acid, 5-((((2s)-2-amino-3-(4-(aminocarbonyl)-2,6-dimethylphenyl)-1-oxopropyl)((1s)-1-(5-phenyl-1h-imidazol-2-yl)ethyl)amino)methyl)-2-methoxy-

15. Eluxadoline [usan:inn]

16. Unii-45tpj4mbq1

17. Benzoic Acid, 5-[[[(2s)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1s)-1-(5-phenyl-1h-imidazol-2-yl)ethyl]amino]methyl]-2-methoxy-

18. Viberzi (tn)

19. Eluxadoline [mi]

20. Eluxadoline [inn]

21. Eluxadoline [who-dd]

22. Gtpl7691

23. Dea No. 9725

24. Eluxadoline [nflis-drug]

25. Schembl12971682

26. Schembl17950908

27. Dtxsid70235589

28. Eluxadoline [orange Book]

29. Amy39829

30. Ex-a1169

31. Mfcd28386164

32. Zinc14210876

33. Akos030632800

34. Ccg-270093

35. Cs-3855

36. Db09272

37. Jnj27018966

38. Ncgc00485958-01

39. Ac-30329

40. As-35135

41. Hy-12247

42. Ft-0701295

43. J3.535.064k

44. A14085

45. D10403

46. Q20539232

47. 5-((((2s)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)propanoyl)((1s)-1-(4-phenyl-1h-imidazol-2-yl)ethyl)amino(methyl)-2-methoxybenzoic Acid

48. 5-(((s)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)-n-((s)-1-(4-phenyl-1h-imidazol-2-yl)ethyl)propanamido)methyl)-2-methoxybenzoic Acid

49. 5-((2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)-n-(1-(5-phenyl-1h-imidazol-2-yl)ethyl)propanamido)methyl)-2-methoxybenzoic Acid

50. 5-[[[(2s)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)propanoyl]-[(1s)-1-(4-phenyl-3h-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic Acid

51. 5-[[[(2s)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)propanoyl]-[(1s)-1-(5-phenyl-1h-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic Acid

2.4 Create Date
2006-10-26
3 Chemical and Physical Properties
Molecular Weight 569.6 g/mol
Molecular Formula C32H35N5O5
XLogP30.9
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count7
Rotatable Bond Count11
Exact Mass569.26381923 g/mol
Monoisotopic Mass569.26381923 g/mol
Topological Polar Surface Area165 Ų
Heavy Atom Count42
Formal Charge0
Complexity917
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

For the treatment of irritable bowel syndrome with diarrhea (IBS-D).


FDA Label


Truberzi is indicated in adults for the treatment of irritable bowel syndrome with diarrhoea (IBS D).


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Gastrointestinal Agents

Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)


5.2 FDA Pharmacological Classification
5.2.1 Active Moiety
ELUXADOLINE
5.2.2 FDA UNII
45TPJ4MBQ1
5.2.3 Pharmacological Classes
mu-Opioid Receptor Agonist [EPC]; Opioid mu-Receptor Agonists [MoA]
5.3 ATC Code

A07


A - Alimentary tract and metabolism

A07 - Antidiarrheals, intestinal antiinflammatory/antiinfective agents

A07D - Antipropulsives

A07DA - Antipropulsives

A07DA06 - Eluxadoline


5.4 Absorption, Distribution and Excretion

Absorption

The oral absorption of eluxadoline is poor - estimated to be 1.02%, this could be attributed to poor in vitro GI permeability, and its zwitterionic nature leading to a negatively charged molecule across the GI pH range.


Route of Elimination

82% excreted in feces, <1% excreted in urine.


5.5 Metabolism/Metabolites

The metabolism of eluxadoline is currently unclear, however evidence suggests limited glucoronidation forms an acyl glucuronide metabolite that is then excreted into urine.


5.6 Biological Half-Life

The mean plasma elimination half-life ranged from 3.7 hours to 6 hours.


5.7 Mechanism of Action

Eluxadoline is a mu-opioid receptor agonis, kappa opioid receptor agonist and a delta opioid receptor antagonist. Eluxadoline is used for diarrhea predominant IBS because it reduces intestinal contractility and normalizes stress-induced acceleration of upper GI transit. Antagonistic activity at the delta receptor minimizes the constipating effect usually seen by mu-opioid receptor agonists alone. Because of it's limited systemic bioavailability, there may be less side effects associated with the use of eluxadoline in comparison with other therapies used to treat diarrhea predominant IBS.


API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1679250600,"product":"ELUXADOLINE(FCI 2853)STAGE-II(T-3328)(QT","address":"PIRAMAL ANANTA, PIRAMAL AGASTYA PAR KAMANI JUNCTION, LBS MARG,","city":"KURLA, MUMBAI","supplier":"PIRAMAL PHARMA SOLUTIONS","supplierCountry":"INDIA","foreign_port":"CHICAGO O\\'HARE INT\\'L","customer":"PATHEON PHARMACEUTICALS, INC.","customerCountry":"UNITED STATES","quantity":"0.00","actualQuantity":"0.5","unit":"GMS","unitRateFc":"13790","totalValueFC":"6869.3","currency":"USD","unitRateINR":1130000,"date":"20-Mar-2023","totalValueINR":"565000","totalValueInUsd":"6869.3","indian_port":"HYDERABAD AIR","hs_no":"29379020","bill_no":"8610044","productDescription":"Intermediate","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PIRAMAL ANANTA, PIRAMAL AGASTYA PAR KAMANI JUNCTION, LBS MARG,, KURLA, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1705689000,"product":"ELUXADOLINE(FCI 2853)PACKING(STAGE-II)(QTY:0.500 GMS)","address":"PIRAMAL ANANTA, PIRAMAL AGASTYA PARK","city":"KURLA, MUMBAI","supplier":"PIRAMAL PHARMA SOLUTIONS","supplierCountry":"INDIA","foreign_port":"CHICAGO O\\'HARE INT\\'L","customer":"SSRC THERMO FISHER SCIENTIFIC","customerCountry":"UNITED STATES","quantity":"0.00","actualQuantity":"0.5","unit":"GMS","unitRateFc":"13790","totalValueFC":"6831.8","currency":"USD","unitRateINR":1135606.5,"date":"20-Jan-2024","totalValueINR":"567803.25","totalValueInUsd":"6831.8","indian_port":"Hyderabad Air","hs_no":"29379020","bill_no":"6907651","productDescription":"Intermediate","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PIRAMAL ANANTA, PIRAMAL AGASTYA PARK, KURLA, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1725215400,"product":"ELUXADOLINE(FCI 2853) PACKING (INVOICE NO.7005152340 DT:26.08.2024)","address":"PIRAMAL ANANTA, PIRAMAL AGASTYA PARK","city":"KURLA, MUMBAI","supplier":"PIRAMAL PHARMA SOLUTIONS","supplierCountry":"INDIA","foreign_port":"CHICAGO O\\'HARE INT\\'L","customer":"PATHEON","customerCountry":"UNITED STATES","quantity":"332.69","actualQuantity":"332.69","unit":"KGS","unitRateFc":"1050","totalValueFC":"346401.5","currency":"USD","unitRateINR":87255,"date":"02-Sep-2024","totalValueINR":"29028865.95","totalValueInUsd":"346401.5","indian_port":"Hyderabad Air","hs_no":"29379090","bill_no":"3680399","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PIRAMAL ANANTA, PIRAMAL AGASTYA PARK, KURLA, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1725215400,"product":"ELUXADOLINE(FCI 2853) PACKING (INVOICE NO.7005152340 DT:26.08.2024)","address":"PIRAMAL ANANTA, PIRAMAL AGASTYA PARK","city":"KURLA, MUMBAI","supplier":"PIRAMAL PHARMA SOLUTIONS","supplierCountry":"INDIA","foreign_port":"CHICAGO O\\'HARE INT\\'L","customer":"PATHEON","customerCountry":"UNITED STATES","quantity":"332.69","actualQuantity":"332.69","unit":"KGS","unitRateFc":"1050","totalValueFC":"346401.5","currency":"USD","unitRateINR":87255,"date":"02-Sep-2024","totalValueINR":"29028865.95","totalValueInUsd":"346401.5","indian_port":"Hyderabad Air","hs_no":"29379090","bill_no":"3690555","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PIRAMAL ANANTA, PIRAMAL AGASTYA PARK, KURLA, MUMBAI","customerAddress":""}]
20-Mar-2023
02-Sep-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Direct Compression

read-more
read-more

Coating Systems & Additives

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Controlled & Modified Release

read-more
read-more

Lubricants & Glidants

read-more
read-more

Co-Processed Excipients

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Taste Masking

read-more
read-more

Granulation

read-more
read-more

Topical

read-more
read-more

Parenteral

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Solubilizers

read-more
read-more

API Stability Enhancers

read-more
read-more

Emulsifying Agents

read-more
read-more

Coloring Agents

read-more
read-more

Rheology Modifiers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty